How early lung cancer detection doubled survival rates

Executive overview

Lung cancer survival rates were stuck near 10% because tumors were only caught late, when lesions were large and hard to biopsy safely. Dorian Averbuch applied electromagnetic navigation to bronchoscopy, enabling minimally invasive access to peripheral lung lesions for the first time. His second company, BodyVision, pushed further with real-time imaging to reach even smaller lesions where survival tops 90%.

Catching lung cancer small is the only reliable way to beat it.

The lung biopsy problem

• Lung lesions are enclosed within the chest, surrounded by ribs, organs, and blood vessels
• Traditional biopsy carried high risk; doctors had to weigh risk against benefit
• Flexible bronchoscopes could only reach lesions near the airway — peripheral lesions were inaccessible
• Survival rate for large lung lesions was ~10–15% at the time

Superdimension: electromagnetic navigation to the lesion

• Sensor on the tip of a flexible bronchoscopy tool tracked its position in real time
• CT scan used pre-operatively to build a 3D map — navigation worked like GPS in a car
• Doctors could guide tools to peripheral lesions and take biopsy through the working channel
• FDA clearance received in 2006; became standard of care within 10 years
• 70,000 patients treated; $70M in sales; acquired by Covidien in 2012 for $350M

The remaining gap and BodyVision

• Superdimension worked only for larger lesions; small lesions (5–15mm) remained out of reach
• Small lesions have ~90% survival rate — reaching them was the key unsolved problem
• BodyVision used real-time C-arm imaging during bronchoscopy to reveal invisible small lesions
• Diagnostic yield exceeded 90%, comparable to CT-guided biopsy
• Technology is accessible to any doctor worldwide and is now a standard of care

Dorian's product development framework

• Start from the end: define the problem and solution before touching technology
• Have a fast conversation with a doctor early — their excitement (or lack of it) is a signal
• Build the earliest possible prototype to make the concept tangible
• Show the mock-up to doctors: their practical questions reveal whether the solution is viable
• Identify the minimum feature set that makes doctors want to use the product

Building medical products: three customers

• The doctor who uses the product
• The medical institution that purchases it
• Regulatory bodies (FDA, European authorities) that must approve it
• Usability gaps between how engineers plan a product and how doctors want to work are common
• Regulatory timelines are long — strategy must be planned from the start
• Technology alone is not enough; it must satisfy clinical, usability, and regulatory needs

Next challenge: back pain

• 70 million people in the US suffer from back pain; 26 million have acute back pain
• Only 1 million receive a permanent solution, creating a $50B market
• Current solutions are locked in hospitals requiring expensive equipment
• Goal: move procedures to ambulatory centers — safer, more efficient, better economics for all
• 80 million work days lost collectively to back pain annually